Compare ILMN & ZTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ILMN | ZTS |
|---|---|---|
| Founded | 1998 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.3B | 32.5B |
| IPO Year | 2000 | 2012 |
| Metric | ILMN | ZTS |
|---|---|---|
| Price | $211.37 | $73.97 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 17 | 12 |
| Target Price | $124.24 | ★ $154.18 |
| AVG Volume (30 Days) | 1.6M | ★ 3.7M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.86% |
| EPS Growth | ★ 170.87 | 10.05 |
| EPS | 2.22 | ★ 3.08 |
| Revenue | $4,343,000,000.00 | ★ $9,467,000,000.00 |
| Revenue This Year | $6.47 | $5.63 |
| Revenue Next Year | $5.58 | $4.77 |
| P/E Ratio | $95.07 | ★ $23.90 |
| Revenue Growth | N/A | ★ 2.28 |
| 52 Week Low | $88.00 | $71.00 |
| 52 Week High | $231.81 | $149.75 |
| Indicator | ILMN | ZTS |
|---|---|---|
| Relative Strength Index (RSI) | 54.52 | 44.06 |
| Support Level | $182.76 | $73.02 |
| Resistance Level | $231.81 | $78.74 |
| Average True Range (ATR) | 9.45 | 2.10 |
| MACD | -0.77 | -0.10 |
| Stochastic Oscillator | 51.24 | 3.11 |
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns roughly 35% of total revenue from production animals (cattle, pigs, poultry, and so on) and nearly 65% from companion animal (dogs, horses, cats) products. Its US business is skewed even more heavily toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.